Welcome to our dedicated page for Jasper Therapeutics news (Ticker: JSPR), a resource for investors and traders seeking the latest updates and insights on Jasper Therapeutics stock.
Jasper Therapeutics, Inc. (Nasdaq: JSPR) is a clinical-stage biotechnology company dedicated to advancing safer and more effective conditioning agents and stem cell engineering to expand the usage of hematopoietic stem cell transplants and gene therapies. Jasper’s primary focus is the clinical development of its lead compound, JSP191, a conditioning antibody designed to clear hematopoietic stem cells from the bone marrow of patients undergoing stem cell transplants. This innovative approach is aimed at reducing the risks associated with current conditioning regimens, thereby making stem cell transplants and gene therapies more accessible and safer for patients.
Jasper Therapeutics is at the forefront of developing novel therapies that target CD117, aiming to address several critical needs in the treatment of mast cell-driven diseases. Recent developments include the ongoing research and presentations related to their compound Briquilimab. These studies demonstrate promising results in preventing passive systemic anaphylaxis and allergic asthma in animal models, indicating potential applications in human allergic conditions.
In recent corporate developments, Jasper announced the fiscal quarter and year-end results for December 31, 2023, highlighting key advancements and strategic growth initiatives. The company also reported the inducement equity incentive plan aimed at attracting and retaining skilled employees, crucial for maintaining its innovative edge.
Jasper Therapeutics is continually building strategic partnerships and collaborations to support its research and development efforts. The company is committed to pushing the boundaries of biotechnology to improve patient outcomes and make curative therapies more broadly available.
For the latest updates, presentations, and financial information, investors and stakeholders are encouraged to contact Joyce Allaire, Alex Gray, or Lauren Walker for further details.
Jasper Therapeutics (Nasdaq: JSPR), a clinical-stage biotech firm specializing in briquilimab, an antibody therapy for mast cell-driven diseases, announced the appointment of Svetlana Lucas, Ph.D., to its Board of Directors, effective June 18, 2024. Dr. Lucas brings over 20 years of experience in strategy, commercialization, and business development, notably in immunology and oncology. She has held key roles at Scribe Therapeutics, Tizona Therapeutics, and Amgen. Her appointment follows the departure of Anna French, a founding investor and Board member. Dr. Lucas expressed enthusiasm for contributing to Jasper's growth and the potential of briquilimab to address various diseases.
Jasper Therapeutics, a biotech firm, will present at the Oppenheimer Novel Targets in Immunology Summit on June 24, 2024, in New York City. The company specializes in briquilimab, an antibody therapy targeting c-Kit (CD117) to treat mast cell-driven diseases like chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and asthma. The presentation, scheduled for 11:45 a.m. EDT, will be a panel discussion on 'Novel Immunological Mechanisms for Dermatologic Disorders'.
Jasper Therapeutics (Nasdaq: JSPR) presented preclinical data on briquilimab at the 2024 EHA Hybrid Congress in Madrid. This study focused on the impact of briquilimab, a novel antibody therapy targeting c-Kit (CD117), on hematopoietic stem cells (HSCs). The findings indicate that while briquilimab blocks SCF/c-Kit signaling, it does not cause apoptosis in healthy HSCs. Instead, it promotes HSC differentiation into CD34- cells with higher c-Kit expression but without increased CD38 expression. These results support briquilimab's safety profile for treating mast cell-driven diseases like chronic urticaria and asthma.
Jasper Therapeutics will present data on briquilimab at the EAACI Congress 2024 in Valencia, Spain from May 31 to June 3. Briquilimab, a novel antibody targeting c-Kit (CD117), aims to treat mast cell-driven diseases like asthma, chronic spontaneous urticaria (CSU), and chronic inducible urticaria (CIndU). Key findings include briquilimab's ability to deplete mast cells and improve lung function in asthma models, as well as reduce dermal mast cells and inflammatory leukocytes in atopic dermatitis (AD) models. A healthy volunteer study showed briquilimab is well-tolerated, with promising pharmacokinetic and pharmacodynamic profiles. The data supports ongoing BEACON and SPOTLIGHT trials in CSU and CIndU. Jasper plans to begin a Phase 1b/2a trial in asthma later in 2024.
Jasper Therapeutics (Nasdaq: JSPR) will present at the Jefferies Global Healthcare Conference on June 5, 2024, at 4:00pm EDT. The biotechnology company, focused on developing briquilimab for diseases like chronic spontaneous urticaria, chronic inducible urticaria, and asthma, will provide a live webcast of the presentation on their Investor Relations website. The presentation will also be archived for 30 days.
Jasper Therapeutics (Nasdaq: JSPR), a biotechnology company developing briquilimab for mast cell-driven diseases, announced its Q1 2024 financial results and corporate updates.
Key progress includes enrollment in Phase 1b/2a BEACON and SPOTLIGHT studies for chronic urticarias, with initial data expected in Q3 and H2 2024.
Jasper is also advancing briquilimab for asthma, starting enrollment in Q4 2024.
Financially, Jasper reported a net loss of $13.7 million, with cash reserves of $118.5 million, extending its runway through Q3 2025 after a $50 million stock offering in February 2024.
Other developments include positive data on briquilimab for CGD and MDS, and the issuance of inducement stock options to new employees.
Jasper Therapeutics, Inc. (Nasdaq: JSPR) announced the initiation of a Phase 1b/2a study evaluating briquilimab in asthma patients in Q4 2024. Briquilimab targets mast cell-driven diseases like chronic spontaneous urticaria and chronic inducible urticaria. The company presented promising preclinical data at the recent AAAAI annual meeting, demonstrating the depletion of mast cells in the airways and prevention of allergen-induced asthmatic responses. Jasper plans to host a KOL webinar on May 20, 2024, featuring Professor Joshua Boyce to discuss the potential of briquilimab in asthma.
Jasper Therapeutics, Inc. (Nasdaq: JSPR) will present at upcoming investor conferences in May to discuss the development of briquilimab, a novel antibody therapy addressing mast cell driven diseases. The company's management will participate in panel discussions at Capital One Securities Biotech/Biopharma Disruptors Event and in a fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference.
FAQ
What is Jasper Therapeutics' main focus?
What is JSP191?
What recent developments has Jasper Therapeutics announced?
What are the key applications of Briquilimab?
How does Jasper Therapeutics support its research efforts?
How can investors get more information about Jasper Therapeutics?
What is the role of CD117 in Jasper Therapeutics' research?
Where can I find Jasper Therapeutics' financial reports?
What is the goal of Jasper Therapeutics' equity incentive plan?
What diseases is Jasper Therapeutics targeting with its therapies?
